Cargando…

Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells

Tamoxifen (TAM) is a nonsteroidal antiestrogen drug, used in the prevention and treatment of all stages of hormone-responsive breast cancer. Simvastatin (SIM), a lipid-lowering agent, has been shown to inhibit cancer cell growth. The study aimed at investigating the impact of using SIM with TAM in e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibrahim, Amel B., Zaki, Hala F., Ibrahim, Walaa W., Omran, Mervat M., Shouman, Samia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880098/ https://www.ncbi.nlm.nih.gov/pubmed/31788433 http://dx.doi.org/10.1016/j.toxrep.2019.10.016

Ejemplares similares

Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells
por: Ibrahim, Amel B, et al.
Publicado: (2019)

Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines
por: Sharaky, Marwa, et al.
Publicado: (2020)

Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines
por: Attia, Yasmin M., et al.
Publicado: (2015)

Modulation of Tamoxifen Cytotoxicity by Caffeic Acid Phenethyl Ester in MCF-7 Breast Cancer Cells
por: Motawi, Tarek K., et al.
Publicado: (2016)

Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients
por: Omran, Mervat M., et al.
Publicado: (2020)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
por: Hamza, Marwa S, et al.
Publicado: (2022)

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
por: Mo, Zhiqiang, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine Administered as an Adjunct to Bupivacaine for Transversus Abdominis Plane Block in Patients Undergoing Lower Abdominal Cancer Surgery
por: El Sherif, Fatma A, et al.
Publicado: (2022)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
por: Omran, Mervat M., et al.
Publicado: (2022)

Enhanced photothermal heating and combination therapy of gold nanoparticles on a breast cell model
por: Faid, Amna H., et al.
Publicado: (2022)

Development of Sedative Dexmedetomidine Sublingual In Situ Gels: In Vitro and In Vivo Evaluations
por: Allam, Ayat A., et al.
Publicado: (2022)

Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells
por: Liang, Zheyong, et al.
Publicado: (2017)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Effectiveness of Coelatura aegyptiaca Extract Combination with Atorvastatin on Experimentally Induced Hyperlipidemia in Rats
por: Mohamed, Ayman Saber, et al.
Publicado: (2019)

Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients
por: Miranda, Carla, et al.
Publicado: (2021)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Combination Treatment of Tamoxifen with Risperidone in Breast Cancer
por: Yeh, Wei-Lan, et al.
Publicado: (2014)

Adverse effect of Tamarindus indica and tamoxifen combination on redox balance and genotoxicity of breast cancer cell
por: Guneidy, R. A., et al.
Publicado: (2023)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011)

Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
por: Jindal, Alka, et al.
Publicado: (2015)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Simvastatin induced ferroptosis for triple-negative breast cancer therapy
por: Yao, Xianxian, et al.
Publicado: (2021)

Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography
por: Gierach, Gretchen L., et al.
Publicado: (2022)

The Combination of α-Tocopheryl Succinate and Sodium Selenite on Breast Cancer: A Merit or a Demerit?
por: Badr, Doaa M., et al.
Publicado: (2016)

Fabrication and Assessment of Orodispersible Tablets Loaded with Cubosomes for the Improved Anticancer Activity of Simvastatin against the MDA-MB-231 Breast Cancer Cell Line
por: Zaki, Randa Mohammed, et al.
Publicado: (2023)

Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells
por: To, Ngoc Bao, et al.
Publicado: (2022)

Stereological Comparison of the Effects of Pentoxifylline, Captopril, Simvastatin, and Tamoxifen on Kidney and Bladder Structure After Partial Urethral Obstruction in Rats
por: Shirazi, Mehdi, et al.
Publicado: (2014)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Myocardial infarction risk and tamoxifen therapy for breast cancer
por: Geiger, A M, et al.
Publicado: (2005)

An epigenomic approach to therapy for tamoxifen-resistant breast cancer
por: Feng, Qin, et al.
Publicado: (2014)

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
por: Bekele, Raie T., et al.
Publicado: (2016)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kh1tqjdija85f6iptsi74cag4j